---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055679"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:43:20.741333+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics reports Q1 2026 net loss $2.0M, FDA agrees to Phase 3 design for VCN-01 in PDAC

## Summary
- Cash and cash equivalents $14.4M as of March 31, 2026; cash runway into Q1 2027.
- FDA alignment on Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel in metastatic PDAC.
- New VIRAGE Phase 2b data at AACR 2026 shows improved OS and PFS across subgroups including liver metastases.
- Compassionate use of VCN-01 in retinoblastoma started; Phase 2/3 trial expected first patient Dec 2026.
- R&D expenses fell 88% to $355K as VIRAGE trial completed; G&A rose 43% to $2.1M.

## SEC filing metadata
- accession: 0001104659-26-055679
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055679
- JSON: https://secwatch.observer/filing/0001104659-26-055679.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055679.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.
  - Period: quarter ended March 31, 2026
  - Result: reported results
  source text: On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.